Vanguard Capital Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
BBA
Vanguard Capital Management's DNLI Position: Q3 2026 in Review
Vanguard Capital Management increased its Denali Therapeutics (DNLI) stake by 7.6% in Q3 2026, buying an estimated $11.1M and bringing the position to 6,751,225 shares worth $140M. The position accounts for ﹤0.01% of the portfolio, ranked #1323.
Vanguard Capital Management first reported a position in DNLI in Q1 2026 and has held it in 3 quarters since. The position peaked at $161M in Q2 2026. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- Vanguard Capital Management held 6,751,225 shares of Denali Therapeutics worth $140M as of Q3 2026.
- Vanguard Capital Management bought 475,496 Denali Therapeutics shares in Q3 2026, an estimated $11.1M.
- Denali Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1323 holding.
- Vanguard Capital Management first reported a position in Denali Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Denali Therapeutics position peaked at $161M in Q2 2026.
- 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.